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SUMMARY
The activity and circulation of influenza viruses in Argentina was studied during 2012 as part
of the Argentinean Surveillance for Influenza and other Respiratory Viruses, in the context of
Global Influenza Surveillance. The antigenicity and molecular characteristics of haemagglutinins
(HA) of circulating influenza A and B viruses were analysed to assess the emergence of virus
variants. Susceptibility to oseltamivir and zanamivir was evaluated by enzymatic assay and
results were backed-up by sequencing of the neuraminidase (NA) genes. During the 2012 season,
influenza virus circulation in Argentina was detected from weeks 24 to 51. The HA sequences of
the studied A(H1N1)pdm09 subtype viruses segregated in a different genetic group compared to
those identified during the 2009 pandemic, although they were still closely related antigenically to
the vaccine virus A/California/07/2009. The HA sequences of the A(H3N2) viruses analysed fell
into the A/Victoria/208/2009 clade, genetic group 3C. A mixed circulation of virus variants
belonging to B/Victoria and B/Yamagata lineages was detected, with B/Victoria being dominant.
All viruses tested were sensitive to oseltamivir and zanamivir except one. This isolate, an
A(H1N1)pdm09 virus possessing the substitution NA-N295S, showed highly reduced inhibition
by oseltamivir and reduced inhibition by zanamivir. Virological and epidemiological surveillance
remains critical for detection of evolving influenza viruses.
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INTRODUCTION
Seasonal influenza is a public health problem that
affects 5–20% of the world’s population annually
causing high morbidity and mortality, especially in
risk groups [1], and the range of type A viruses, largely
maintained in avian species, poses potential pandemic
threats [2].
Types A and B influenza viruses cause epidemic dis-
ease in humans. Influenza A viruses are further clas-
sified into subtypes according to the characteristics
of two surface glycoproteins: haemagglutinin (HA)
and neuraminidase (NA). Currently, two lineages of
influenza B viruses co-circulate. Influenza viruses dis-
play high rates of mutation, most marked in the genes
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encoding the glycoproteins HA and NA which are
under the greatest selection pressures by host immune
systems [3].
Minor changes in HA and NA can result in the
emergence of antigenically drifted viruses. Antigenic
drift of influenza A HA is a well-studied evolutionary
process, in terms of both the timing and the amino
acid locations of changes that lead to important anti-
genic variation [4]. Through zoonotic events,
influenza A viruses can undergo antigenic shifts, anti-
genic changes of greater magnitude that are respon-
sible for the emergence of new subtypes, which may
result in a widespread pandemic in an immunologic-
ally naive human population [5]. Identification and
characterization of circulating influenza viruses is es-
sential for detection of the emergence of such antige-
nically drifted/shifted viruses in different regions of
the world.
Trivalent inactivated influenza virus vaccines are
widely used throughout the world, with approximately
300 million doses [6]. The antigen content of vaccines
needs to be monitored on an annual basis and updated
frequently, due to the variability of influenza viruses
[7, 8]. The WHO coordinates influenza surveillance
throughout the world, which is important for the de-
tection and identification of newly emerging epidemic
variants, and contributes to the biannual selection of
appropriate vaccine strains [9]. The trivalent vaccine
formulation recommended by WHO for the Southern
Hemisphere 2012 influenza season contained the fol-
lowing: A/Perth/16/2009-like (H3N2), A/California/
07/2009-like (H1N1)pdm09 and B/Brisbane/60/
2008-like (Victoria lineage) virus components [10].
Vaccines are the most effective primary strategy
available for preventing and lowering the impact of
an influenza outbreak. Otherwise, antiviral drugs can
be used in prevention and treatment of influenza, result-
ing in lower mortality and morbidity. Antiviral drugs
for influenza currently include two classes: M2 ion
channel inhibitors amantadine and rimantadine, and
neuraminidase inhibitors (NAIs) oseltamivir (Tamiflu)
and zanamivir (Relenza) [11, 12]. Prior to 2009, NAI
use was largely restricted to Japan and the USA; the
onset of the pandemic in 2009 brought with it a sharp
increase in NAI usage in many countries [13]. With
increased drug use, the likelihood of resistance develop-
ing increases. Due to the global spread of adamantane
resistance, it has been recommended discontinue the
use of M2 ion channel inhibitors. This showed that
antiviral-resistant influenza viruses represent a genuine
public health risk [13]. In the USA, from 2009 to 2011,
0·9–1·1% of influenza A(H1N1)pdm09 viruses and
0·2% of influenza A(H3N2) were oseltamivir resistant,
while almost 100% of A(H1N1)pdm09 and A(H3N2)
viruses were adamantane resistant. Therefore, surveil-
lance for resistance is important in terms of prevention
and treatment of influenza infection [11].
The aims of this study were to evaluate the 2012
influenza season in Argentina and determine the
virus characteristics of a subset of circulating influenza
A and B viruses to include monitoring of their suscep-
tibility to antiviral drugs.
MATERIALS AND METHODS
Specimen collection and influenza detection/diagnosis
Weekly influenza virological surveillance in Argentina
is conducted routinely by the WHO National
Influenza Centre (NIC) located in Buenos Aires as
part of the WHO’s Global Influenza Surveillance
and Response System (GISRS).
The NIC, as the National Laboratory for Influenza
and Respiratory Viruses (NLIVR), conducts the sur-
veillance activities with the National Laboratory
Network, composed of 65 laboratories distributed
throughout the country. This ensures efficient moni-
toring of virus circulation with approximately 70 000
respiratory samples per year being submitted for diag-
nostic testing. Nasopharyngeal aspirates and throat or
nasal swabs from paediatric and adult outpatients and
inpatients with acute respiratory infection are col-
lected and examined by immunofluorescence assay
(IFA) [14] for diagnosis of influenza A, influenza B,
and other respiratory viruses, including respiratory
syncytial virus (RSV), adenovirus, and parainfluenza
virus. IFA negative samples are also studied by one-
step real-time reverse transcriptase–polymerase chain
reaction (rtRT–PCR) assay using primer/probe sets
against regions of two different genes: the M gene of
influenza type A virus and the nucleoprotein (NP)
gene of influenza type B virus, using the Centers for
Disease Control and Prevention (CDC, USA)
influenza diagnosis protocols. The influenza-positive
clinical samples, types A and B, are routinely submit-
ted to the NIC for further characterization. In 2012,
the NIC received almost 2400 influenza-positive sam-
ples from the national network.
Subtype determination and virus isolation
All influenza A samples are routinely subtyped by one-
step rtRT–PCR assay using specific primer/probe sets
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for the HA gene recommended by the CDC. Of the
influenza-positive specimens received by the NIC in
the 2012 influenza season, 824 (35%) were selected for
isolation in mammalian cells taking into account the
specimens’ collection dates, preservation conditions,
and the geographical locations in order to obtain virus
isolates from different regions of the country through-
out the study period. Parental Madin–Darby canine
kidney (MDCK) cells were used for isolation of
A(H1N1)pdm09 and B viruses and MDCK-SIAT1
cells (engineered to express increased levels of
sialyl-α2,6-galactose moieties) for A(H3N2) viruses
[15]. MDCK andMDCK-SIAT1 cells were maintained
in Minimum Essential Medium with Earle’s salts,
non-essential amino acids and L-glutamine (Gibco
no. 41-500-034) and Dulbecco’s Modified Eagle’s
Medium (Gibco no. 12 800-01) respectively, both sup-
plemented with 2% fetal bovine serum (Gibco, USA).
The presence of virus in tissue-culture supernatant was
assessed by direct IFA and/or haemagglutination
assay (HA) according to standard methods using sus-
pensions of guinea pig red blood cells (GPRBC,
0·75% v/v) [16] performed no later than 7 days post-
infection. Thirty-nine influenza isolates [two influenza
A(H3N2), 26 A(H1N1)pdm09 and 11 B viruses] with
collection dates in July and August [epidemiological
weeks (EW) 27–35] from different provinces of the
country with the purpose of achieving a geographical re-
presentation were sent to the WHO Collaborating
Center for Reference and Research on Influenza
(WHO CC), London, UK, for comprehensive anti-
genic, genetic and antiviral drug susceptibility studies.
Written informed consent and explicit ethical
approval were not sought as this study was an obser-
vational undertaking as part of routine virological
surveillance (performed anonymously, without iden-
tification of patients), as established in the terms of
reference for WHO National Influenza Centres.
Antigenic characterization
A total of 33 isolates were antigenically characterized
by haemagglutination inhibition (HI) tests as follows:
20 influenza A(H1N1)pdm09, two A(H3N2) and 11
influenza B. HI testing was performed using a panel
of post-infection ferret antisera using turkey red
blood cells for H1N1 and B viruses [17]. For H3N2
viruses assays were performed with GPRBC in the
presence of 20 nM oseltamivir to circumvent the
NA-mediated binding of H3N2 viruses to the red
blood cells [18].
NAI susceptibility assay
Analysis of NA susceptibility was performed on 16
influenza A(H1N1)pdm09, two A(H3N2) and 10
influenza B isolates. NA activity was measured using
the fluorescent substrate, 2’-(4-methylumbelliferyl)-
α-D-N-acetylneuraminic acid (MUNANA; Sigma,
USA) [19]. Briefly, 15 μl virus was incubated with 30 μl
of 100 μM MUNANA in 32·5 mM MES buffer (pH
6·5) containing 4 mM CaCl2 for 1 h at 37 °C. The reac-
tion was stopped by addition of 150 μl of 0·14 M
NaOH in 83% ethanol and fluorescence of the released
4-methylumbelliferone was measured at excitation and
emissionwavelengths of 365 nmand 450 nm, respective-
ly. The activity of each virus sample was titrated, by
assaying serial twofold dilutions and virus suspensions
were adjusted to equivalent NA activities, which fell in
the linear portion of the activity curve. Each virus was
pre-incubated for 30 min at 37 °C with oseltamivir or
zanamivir at final concentrations of 5 μM-0·05 pM, in
serial tenfold dilutions, NA activity measured and the
drug concentration that inhibited 50% of the neuramin-
idase (IC50) was determined [20].
Gene sequencing and analysis
RNA was extracted from propagated viruses and HA
and NA genes amplified using one-step rtRT–PCR.
Gene sequences were determined by the Sanger method
using an ABI 3730XL capillary sequencer. Sequences
of primers used for gene amplification and Sanger se-
quencing can be obtained on request. Phylogenetic ana-
lysis of the nucleotide sequences was performed using
RaxML (sco.h-its.org/exelixis/web/software/raxml/) and
the dendograms generated using FigTree (http://tree.
bio.ed.ac.uk/software/figtree/). All sequences determined
in the course of this work have been deposited in the
Global Initiative on Sharing All Influenza Data
(GISAID) database under the following virus identifiers:
EPI_ISL_131 955, EPI_ISL_131 956, EPI_ISL_131 957,
EPI_ISL_131 958, EPI_ISL_131 960, EPI_ISL_131 964,
EPI_ISL_131 965, EPI_ISL_131 966, EPI_ISL_131 969,
EPI_ISL_131 970, EPI_ISL_131 973, EPI_ISL_131 974,
EPI_ISL_131 975, EPI_ISL_131 976, EPI_ISL_131 977,
EPI_ISL_131 978, EPI_ISL_131 979, EPI_ISL_131 980,
EPI_ISL_131 981, EPI_ISL_31 982, EPI_ISL_131 983,
EPI_ISL_131 984, EPI_ISL_131 985, EPI_ISL_131
991, EPI_ISL_131 992, EPI_ISL_132 002, EPI_ISL_
132 003, EPI_ISL_132 251, EPI_ISL_132 252, EPI_
ISL_132 253, EPI_ISL_132 257, EPI_ISL_132 273,
EPI_ISL_132 293, EPI_ISL_132 294, EPI_ISL_132
295, EPI_ISL_132 296, EPI_ISL_132 297.
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RESULTS
Virological surveillance
For 2012, according to information provided by the
Argentinean Ministry of Health (MoH), a total of
68 225 cases of acute respiratory infection were stud-
ied in the laboratory according to the National data-
base (SIVILA), 22 745 were positive for respiratory
viruses. RSV was the most common virus detected,
accounting for 74·9% of the positive cases, followed
by influenza viruses (12·6%) and parainfluenza virus
(6·5%) [21]. The NIC received 2387/2859 (83·5%) of
the influenza-positive samples detected in the country,
of which 2212 were typed/subtyped. Influenza
A(H3N2), A(H1N1)pdm09 and B viruses were
detected from January to December in similar propor-
tions. In 2012, as in previous seasons, influenza activ-
ity peaked late (middle August to late September).
Influenza A(H1N1)pdm09 viruses (666, 30·1%) were
detected sporadically from EW 1–26, increasing
from EW 27–40 with peak detection in EW 36
(early September), while influenza A(H3N2) viruses
(677, 30·6%) were detected from June to December
with peak detection in EW 37 (mid-September).
Influenza B viruses (869, 39·3%) were detected from
EW 25, with peak detection in EW 40 (early
October) (Fig. 1).
Antigenic and genetic characteristics of the viruses
In 2012, the average rate of influenza isolation in tis-
sue culture at the NIC was 56%. A subset of the iso-
lates from the early part of the season, EW 27–35
(Fig. 1), were antigenically and genetically character-
ized at the WHO CC, London, UK. The results of
HI assays performed on influenza A and B isolates
are presented in Tables 1–4.
Influenza A(H1N1)pdm09 viruses
Of the 26 isolates received by the WHO CC, 25 were
recovered but only 20 propagated to sufficient HA
titre to allow HI assays to be performed (Table 1).
Nineteen of the Argentinian viruses showed a very
similar reactivity pattern to each other and reacted
well with the whole panel of antisera. The reactivity
pattern of A/Salta/1122/2012, which carries the
D156D/N polymorphism in HA1, more closely
resembled those of the reference viruses A/Bayern/
69/2009 and A/Lviv/N6/2009 which carry the G155E
substitution and G155E/G polymorphism, respectively,
in their HA1 component. Phylogenetic analysis based
on 25 HA sequences showed that 23 fell in genetic
group 6 with the remaining two falling in genetic
group 7 (Fig. 2). The genetic group 6 viruses clearly
split into two subgroups with four viruses from Salta
being defined by amino acid substitutions K283R
(HA1) and I510T (HA2) and the larger group being
defined by N260T (HA1) substitution and showing
further subdivision based on HA1 substitutions
N38D with V173I, and R45G with V321I. The two
genetic group 7 viruses and three of those falling in
genetic group 6 could not be assayed by HI due to
insufficient HA titres. Phylogenetic trees including
24 of the Argentinian virus NA sequences (data not
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Fig. 1. Influenza-like illness (ILI) surveillance and influenza-positive samples submitted to the National Influenza Centre,
Buenos Aires throughout 2012 in Argentina.
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Table 1. Antigenic analyses of A(H1N1)pdm09 viruses
Haemagglutination inhibition titre
Post-infection ferret antisera
Collection date Passage history A
/
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/
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/
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F
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3
/
1
1
A
/
S
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P
e
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e
r
s
b
u
r
g
/
2
7
/
1
1
F
2
4
/
1
1
Genetic group . . . 4 3 6 7 6
Reference viruses
A/California/7/2009 2009-04-09 E1/E2 1280 1280 1280 640 640 640 640 1280
A/Bayern/69/2009 2009-07-01 MDCK4/MDCK1 80 320 160 80 40 80 80 80
A/Lviv/N6/2009 2009-10-27 MDCK4/SIAT1/
MDCK2
640 1280 1280 320 160 320 320 160
A/Christchurch/16/2010 4 2010-07-12 E2/E2 1280 1280 1280 5120 1280 1280 1280 2560
A/Hong Kong/3934/2011 3 2011-03-29 MDCK2/MDCK2 640 160 320 640 1280 1280 640 1280
A/Astrakhan/1/2011 6 2011-02-28 MDCK1/MDCK5 1280 640 1280 1280 2560 2560 1280 5120
A/St. Petersburg/27/2011 7 2011-02-14 E1/E2 5120 1280 5120 2560 2560 5120 5120 5120
A/St. Petersburg/100/2011 6 2011-03-14 E1/E2 2560 1280 2560 1280 2560 2560 2560 5120
Test viruses
A/Salta/1122/2012 6 2012-07-14 MDCK2/MDCK1 640 640 640 320 320 640 320 640
A/Salta/1121/2012 6 2012-07-15 MDCK2/MDCK1 1280 640 1280 12580 2560 2560 2560 5120
A/Santa Fe/333 171/2012 6 2012-07-20 MDCK1/MDCK1 2560 1280 1280 2560 2560 2560 2560 5120
A/Salta/1363/2012 6 2012-07-26 MDCK2/MDCK1 2560 1280 1280 2560 2560 2560 2560 5120
A/Salta/1341/2012 6 2012-07-26 MDCK2/MDCK1 2560 1280 1280 2560 2560 2560 2560 5120
A/Tucumán/59 232/2012 6 2012-07-27 MDCK2/MDCK1 1280 640 1280 1280 2560 2560 2560 5120
A/Corrientes/66 335/2012 6 2012-08-03 SIAT2/MDCK1 2560 1280 2560 2560 2560 2560 5120 5120
A/Formosa/V2361/2012 6 2012-08-03 SIAT2/MDCK2 5120 2560 5120 5120 5120 5120 5120 5120
A/Tucumán/I1956/2012 6 2012-08-07 MDCK2/MDCK1 2560 640 1280 2560 2560 2560 2560 5120
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Table 1 (cont.)
Haemagglutination inhibition titre
Post-infection ferret antisera
Collection date Passage history A
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/
0
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/
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Genetic group . . . 4 3 6 7 6
A/Misiones/6563/2012 6 2012-08-07 SIAT2/MDCK1 1280 640 1280 2560 2560 2560 2560 5120
A/Misiones/6592/2012 6 2012-08-08 MDCK2/MDCK1 1280 640 1280 1280 2560 2560 2560 5120
A/Tucumán/I1972/2012 6 2012-08-10 SIAT2/MDCK1 2560 640 2560 2560 5120 5120 5120 5120
A/Corrientes/67 120/2012 6 2012-08-15 SIAT2/MDCK1 5120 1280 2560 2560 5120 5120 5120 5120
A/Santa Fe/915 526/2012 6 2012-08-17 SIAT2/MDCK1 5120 1280 2560 2560 5120 5120 5120 5120
A/Catamarca/R4297/2012 6 2012-08-17 SIAT2/MDCK1 2560 1280 2560 2560 5120 5120 2560 5120
A/Santa Fe/1667/2012 6 2012-08-21 SIAT2/MDCK1 2560 1280 2560 2560 5120 5120 5120 5120
A/Misiones/7214/2012 6 2012-08-22 MDCK2 /MDCK1 5120 1280 2560 2560 5120 5120 5120 5120
A/Tucumán/A382/2012 6 2012-08-23 SIAT2/MDCK1 2560 640 1280 1280 2560 2560 2560 5120
A/Tucumán/A480/2012 6 2012-08-31 MDCK1/MDCK1 5120 1280 2560 2560 5120 5120 5120 5120
A/Santa Fe/1532/2012 6 not known MDCK2/MDCK1 2560 640 1280 1280 2660 2560 2560 5120
Vaccine
2012,
2013,
2014
E, Egg; cell type, MDCK or SIAT; number of passages required to generate isolate/subsequent number of passages to produce sufficient virus for HA/HI analyses.
Homologous titres are indicated by underlined italics.
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Table 2. Antigenic analyses of influenza A(H3N2) viruses (guinea pig RBC with 20 nM oseltamivir)
Haemagglutination inhibition titre
Post-infection ferret antisera
Virus Collection date Passage history
A
/
P
e
r
t
h
1
6
/
0
9
F
3
5
/
1
1
A
/
V
i
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t
o
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i
a
/
2
0
8
/
0
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/
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1
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/
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/
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/
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/
1
1
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/
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a
/
3
6
1
/
1
1
E
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/
1
2
A
/
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e
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n
/
9
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/
1
1
F
1
1
/
1
2
A
/
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r
i
a
/
3
6
1
/
1
1
T
/
C
F
1
4
/
1
2
A
/
A
t
h
e
n
s
/
1
1
2
/
1
2
F
1
1
/
1
2
A
/
O
h
i
o
/
2
/
1
2
F
2
7
/
1
2
A
/
S
.
A
u
s
t
r
a
l
i
a
/
3
0
/
1
2
F
2
8
/
1
2
Genetic group . . . 5 3A 6 3C 3C 3C 3B 3B 3A
Reference viruses
A/Perth/16/2009 2009-07-04 E3/E2 1280 80 160 160 160 160 640 640 640 160 160
A/Victoria/208/2009 2009-06-02 E3/E2 1280 5120 1280 2560 5120 5120 5120 5120 5120 1280 5120
A/Alabama/5/2010 5 2010-07-13 MDCK1/C2/SIAT2 < < 80 80 80 40 160 320 320 40 40
A/Stockholm/18/2011 3A 2011-03-28 MDCK2/SIAT5 40 40 80 320 80 160 320 640 320 160 160
A/Iowa/19/2010 6 2010-12-30 E3/E2 160 320 320 640 1280 640 1280 1280 1280 320 320
A/Victoria/361/2011 3C 2011-10-24 E3/E2 320 640 320 160 640 5120 1280 640 320 160 640
A/Berlin/93/2011 3C 2011-12-07 MDCK3/SIAT4 80 80 160 320 320 320 1280 1280 640 320 320
A/Victoria/361/2011 3C 2011-10-24 MDCK2/SIAT2 80 80 160 320 320 320 640 1280 640 320 320
A/Athens/112/2012 3B 2012-02-01 SIAT5 80 160 160 320 320 320 640 1280 1280 320 320
A/Ohio/2/2012 3B 2012-03-08 E4/E1 160 80 640 320 640 160 640 1280 640 1280 160
A/South Australia/30/
2012
3A 2012-05-10 E2/E1 320 160 640 640 640 320 640 1280 640 640 320
Test viruses
A/Buenos Aires/1 004
423/20 112
3C 2012-07-24 SIAT2/SIAT1 160 160 320 640 640 640 1280 1280 1280 640 320
A/Buenos Aires/10
435 982/2012
3C 2012-07-27 SIAT2/SIAT1 160 160 320 640 320 320 1280 1280 1280 320 320
Vaccine
2012
Vaccine
2013
E, Egg; cell type, MDCK or SIAT (C = cell type unspecified); number of passages required to generate isolate/subsequent number of passages to produce sufficient virus for
HA/HI analyses.
< = <40, the ferret reference number is given under the virus name.
Homologous titres are indicated as underlined italics.
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Table 3. Antigenic analyses of influenza B viruses (Victoria lineage)
Haemagglutination inhibition titre
SS Post infection ferret sera
Virus Collection date Passage history
B
/
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/
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0
/
0
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B
/
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/
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1
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1
7
/
1
1
B
/
H
o
n
g
K
o
n
g
/
5
1
4
/
0
9
F
1
3
/
1
0
B
/
O
d
e
s
s
a
/
3
8
8
6
/
1
0
F
1
9
/
1
1
B
/
M
a
l
t
a
/
6
3
6
7
1
4
/
1
1
F
3
3
/
1
1
Reference viruses
B/Malaysia/2506/2004 2004-12-06 E3/E5 1280 640 40 160 < < 10 160
B/England/393/2008 2008-08-29 E1/E1 2560 80 320 640 40 40 80 640
B/Brisbane/60/2008 2008-08-04 E4/E3 1280 80 320 640 40 40 80 320
B/Paris/1762/2008 2009-02-09 C2/MDCK1 5120 10 20 80 80 80 0·8 20
B/Hong Kong/514/2009 2009-10-11 MDCK1/MDCK3 5120 < 20 80 80 80 320 20
B/Odessa/3886/2010 2010-03-19 MDCK2/MDCK1 2560 < 20 40 80 80 160 20
B/Malta/636 714/2011 2011-03-07 E4/E1 2560 80 320 640 40 40 80 640
Test viruses
B/Buenos Aires/770/2012 2012-07-06 MDCK2 /MDCK1 5120 < 20 80 160 80 160 40
B/Formosa/V2367/2012 2012-08-06 MDCK1/MDCK1 5120 < 40 80 160 80 80 40
B/Tucumán/I2010/2012 2012-08-15 MDCK1/MDCK1 2560 10 40 80 80 80 80 40
B/Santa Fe/915 530/2012 2012-08-21 MDCK1/MDCK1 2560 < 20 80 80 80 80 20
B/Tucumán/A458/2012 2012-08-28 MDCK1/MDCK1 2560 < 20 80 80 80 80 20
B/Buenos Aires/R146/2012 not known MDCK1/MDCK1 5120 10 40 80 160 160 160 40
B/Santa Fe/335 651/2012 not known MDCK2 /MDCK1 2560 < 40 80 80 80 80 40
B/Buenos Aires/R335/2012 not known MDCK1/MDCK1 2560 10 40 80 80 80 80 40
B/Tucumán/A423/2012 not known Cx/MDCK2 2560 < 40 80 80 80 80 40
Vaccine
2012, 2013*,
2014*
SS, Hyperimmune sheep antiserum; E, Egg; cell type, MDCK or SIAT (C = cell type unspecified); number of passages required to generate isolate (x = unknown number)/
subsequent number of passages to produce sufficient virus for HA/HI analyses.
< = <10, the sheep/ferret reference number is given under the virus name.
* For use in quadrivalent vaccines including both influenza B lineages.
Homologous titres are indicated as underlined italics.
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Table 4. Antigenic analyses of influenza B viruses (Yamagata lineage)
Haemagglutination inhibition titre
SS Post-infection ferret sera
Virus Collection date Passage history B
/
F
l
o
r
i
d
a
/
4
/
0
6
S
H
4
7
9
B
/
E
g
y
p
t
/
1
4
4
/
0
5
F
3
/
0
7
B
/
F
l
o
r
i
d
a
/
4
/
0
6
F
1
/
1
0
B
/
B
r
i
s
b
a
n
e
/
3
/
0
7
F
2
1
/
1
2
B
/
E
n
g
l
a
n
d
/
1
4
5
/
0
8
F
1
2
/
1
1
B
/
B
a
n
g
l
a
d
e
s
h
/
3
3
3
3
/
0
7
F
2
5
/
0
8
B
/
W
i
s
c
o
n
s
i
n
/
1
/
1
0
F
7
/
1
2
B
/
S
t
o
c
k
h
o
l
m
/
1
2
/
1
1
E
g
g
F
3
4
/
1
1
B
/
E
s
t
o
n
i
a
/
5
5
6
6
9
/
1
1
F
2
6
/
1
1
B
/
S
e
r
b
i
a
/
1
8
9
4
/
1
1
F
2
5
/
1
1
B
/
S
t
o
c
k
h
o
l
m
/
1
2
/
1
1
T
/
C
F
8
/
1
2
Genetic group . . . 1 1 1 2 3 3 3 3 2 3 3
Reference viruses
B/Egypt/144/2005 1 2005-05-01 E3/E5 5120 640 1280 1280 320 640 320 640 160 20 640
B/Florida/4/2006 1 2006-12-15 E3/E3 5120 320 2560 1280 640 640 320 640 160 20 640
B/Brisbane/3/2007 2 2007-09-03 E2/E1 5120 160 640 1280 160 320 160 640 160 10 320
B/England/145/2008 3 not known Ex/E4 640 < 160 80 320 40 40 80 < < 80
B/Bangladesh/3333/2007 3 2007-08-07 E4/E4 5120 80 640 320 80 320 80 640 < 20 640
B/Wisconsin/1/2010 3 2007-08-07 E3/E1 1280 80 320 160 160 160 160 160 10 20 320
B/Stockholm/12/2011 3 2007-08-07 E4/E1 5120 160 640 320 160 320 160 640 10 40 640
B/Estonia/55 669/2011 2 2011-03-14 MDCK2/MDCK2 2560 80 320 160 80 20 20 160 640 80 40
B/Serbia/1894/2011 3 2011-03-08 MDCK1/MDCK4 5120 160 320 160 320 160 80 320 160 320 320
B/Stockholm/12/2011 3 2011-03-28 Cx/MDCK4 5120 80 320 160 160 160 80 640 160 320 320
Test viruses
B/Tucumán/A285/2012 2 2012-08-14 MDCK1/MDCK1 2560 40 160 80 40 10 20 160 640 20 20
B/Buenos Aires/8833/2012 2 2012-08-26 MDCK1/MDCK2 1280 < 80 40 20 10 10 80 320 20 20
Vaccine
2013
SS, Hyperimmune sheep antiserum; E, egg; cell type, MDCK or SIAT (C = cell type unspecified); number of passages required to generate isolate (x = unknown number)/
subsequent number of passages to produce sufficient virus for HA/HI analyses.
< = <10, the sheep/ferret reference number is given under the virus name.
Homologous titres are indicated by underlined italics.
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Fig. 2. Phylogenetic comparison of influenza A(H1N1)pdm09 HA genes. Vaccine virus is indicated in bold red font and
reference viruses (those to which post-infection ferret antisera have been raised) are shown in bold black font. Coloured
font is used to indicate the month of clinical specimen collection for viruses isolated covering April to August 2012.
Isolates from National Influenza Centre, Argentina are boxed. The majority of sequences used in the phylogenetic analysis
were generated by WHO CC, London (all available in GISAID), while others were downloaded from GISAID as
indicated (e.g. cnic, cdc, aus). The scale bar indicates the proportion of nucleotide changes between sequences.
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shown) showed congruency in terms of the genetic
groupings with HA phylogeny.
Influenza A(H3N2) viruses
The two Argentinian A(H3N2) viruses showed poor re-
activity with post-infection ferret antisera raised against
three egg-propagated viruses in terms of reduction, i.e.
eightfold or greater reduction in HI titre compared to
the titres with the homologous viruses: the 2012 A/
Perth/16/2009, and 2013 A/Victoria/361/2011 vaccine
viruses and A/Victoria/208/2009 (Table 2). However,
in terms of absolute titre, reactivity was somewhat bet-
ter with antiserum raised against A/Victoria/361/2011.
The two test viruses reacted better with antisera raised
against the egg-propagated A/Iowa/19/2010, A/Ohio/2/
2012 and A/South Australia/30/2012 reference viruses
compared to the homologous titres. These antisera,
particularly those raised against A/South Australia/
20/2012, had lower homologous titres than other recent
egg-propagated H3N2 viruses. Both test viruses
showed good reactivity with post-infection ferret anti-
sera raised against the five tissue-culture propagated
reference viruses, which included A/Victoria/361/2011.
Phylogenetic analyses of HA (Fig. 3) and NA genes
(data not shown) demonstrated that the two test viruses
fell into the A/Victoria/208/09 clade, genetic group 3C
for both genes.
Influenza B viruses
Of the 11 influenza B viruses studied, nine belonged to
the Victoria lineage (Table 3 and Fig. 4) and two to
the Yamagata lineage (Table 4 and Fig. 5).
All tested viruses belonging to the Victoria lineage
gave the common pattern of reactivity that has been
observed over the course of the previous two seasons:
the viruses reacted with an eightfold reduced titre with
antiserum raised against egg-propagated vaccine
virus, B/Brisbane/60/2008, compared to the homolo-
gous titre (Table 3). However, viruses reacted at titres
similar to the homologous viruses with antisera raised
against influenza B viruses genetically closely related
to the vaccine virus but propagated in cells (B/Paris/
1762/2008, B/Hong Kong/514/2009 and B/Odessa/
3886/2010). Low reactivity was also seen with anti-
serum raised against the egg-propagated virus B/
Malta/636 714/2011 compared to the homologous
titre. Phylogenetic analyses including eight HA and
seven NA (data not shown) genes from the
Argentinian viruses showed that all belonged to the
B/Brisbane/60/2008 genetic clade (Clade 1), with
four of the eight/seven clustering together (Fig. 4).
The two Yamagata lineage viruses reacted well with
antiserum raised against B/Estonia/55 669/2011 and
poorly with antiserum raised against the virus recom-
mended for the 2013 vaccine, B/Wisconsin/1/2010
(Table 4). Generally both test viruses showed poor re-
activity, eightfold or greater reduction in HI titre, with
all antisera raised against the other eight reference
viruses compared to the respective homologous titres,
the one exception being B/Tucuman/A285/2012 which
showed a fourfold drop with antiserum raised against
egg-propagated B/Stockholm/12/2011. Phylogenetic
analyses of HA and NA (data not shown) genes
demonstrated that both test viruses belonged to
clade 2, represented by the reference virus B/Estonia/
55 669/2011.
Antiviral susceptibility results
Phenotypic testing to assess virus susceptibility to the
NAIs, oseltamivir and zanamivir, was performed on a
number of test viruses: 16 A(H1N1)pdm09, two
A(H3N2) and 10 influenza B. The A(H3N2) and
influenza B viruses showed normal inhibition by
both antivirals. Of the 16 A(H1N1)pdm09 viruses
studied, 15 showed normal inhibition by both anti-
virals but one, A/Salta/1341/2012, showed highly
reduced inhibition by oseltamivir (IC50: 187·9 nM)
and reduced inhibition by zanamivir (IC50: 8·3 nM).
NA gene sequencing of this isolate and the original
clinical specimen showed both carried the amino
acid substitution N295S, known to reduce the inhi-
bitory effects of the NAIs studied [22]. The clinical
specimen was taken from a 17-year-old pregnant out-
patient with symptom onset on 25 July 2012 who had
not been vaccinated; on 26 July 2012 oseltamivir treat-
ment was initiated.
DISCUSSION
Clinical surveillance, supported by antigenic and gen-
etic analyses are invaluable in guiding effective
influenza control measures. The influenza pandemic
caused by A(H1N1)pdm09 underscored the import-
ance of surveillance networks that can rapidly charac-
terize circulating viruses for effective response and
containment [23].
The present study reports results of virological
and drug susceptibility surveillance in selected
influenza A(H1N1)pdm09, A(H3N2), and B viruses
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Fig. 3. Phylogenetic comparison of influenza A(H3N2) HA genes. Vaccine virus is indicated in bold red font and
reference viruses (those to which post-infection ferret antisera have been raised) are shown in bold black font. Coloured
font is used to indicate the month of clinical specimen collection for viruses isolated covering April to August 2012.
Isolates from National Influenza Centre, Argentina are boxed. The majority of sequences used in the phylogenetic analysis
were generated by WHO CC, London (all available in GISAID), while others were downloaded from GISAID as
indicated (e.g. cnic, cdc, aus). The scale bar indicates the proportion of nucleotide changes between sequences.
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Fig. 4. Phylogenetic comparison of influenza B (Victoria lineage) HA genes. Vaccine virus is indicated in bold red font
and reference viruses (those to which post-infection ferret antisera have been raised) are shown in bold black font.
Coloured font is used to indicate the month of clinical specimen collection for viruses isolated covering April to August
2012. Isolates from National Influenza Centre, Argentina are boxed. The majority of sequences used in the phylogenetic
analysis were generated by WHO CC, London (all available in GISAID), while others were downloaded from GISAID as
indicated (e.g. cnic, cdc, aus). The scale bar indicates the proportion of nucleotide changes between sequences.
Characterization of influenza virus, Argentina 2012 13
Fig. 5. Phylogenetic comparison of influenza B (Yamagata lineage) HA genes. Vaccine virus is indicated in bold red font
and reference viruses (those to which post-infection ferret antisera have been raised) are shown in bold black font.
Coloured font is used to indicate the month of clinical specimen collection for viruses isolated covering April to August
2012. Isolates from National Influenza Centre, Argentina are boxed. The majority of sequences used in the phylogenetic
analysis were generated by WHO CC, London (all available in GISAID), while others were downloaded from GISAID as
indicated (e.g. cnic, cdc, aus). The scale bar indicates the proportion of nucleotide changes between sequences. For three
virus sequences derived from solely egg or MDCK, cell isolated and propagated viruses are included.
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isolated in Argentina in 2012 when types A and B
influenza viruses of both subtypes and lineages
co-circulated in the human population throughout
the study period.
The transmission pattern of influenza viruses was
different in the four countries of the Southern Cone
in South America in 2012. Increased viral circulation
in the area was first noted at the end of April to
early May in Chile and Paraguay; Argentina and
Uruguay begun to report active transmission in early
June. Surprisingly, peak activities were detected very
late in this region. In Argentina the peak was regis-
tered at the beginning of August, 10 weeks later
than in the last 9 years [24].
In Argentina, before emergence of A(H1N1)pdm09,
seasonal influenza vaccination was recommended and
funded for individuals aged from 6 months having
chronic co-morbidities, pregnant woman and the elder-
ly population aged 565 years [25, 26]. Following the
analysis of the pandemic, the Argentinean MoH con-
sidered it necessary to include among the risk groups
all children aged <5 years [27]; since 2011 this recom-
mendation has been changed to include children aged
from 6 months to 2 years only.
All influenza A(H1N1) viruses detected globally
since January 2010 have been related to A(H1N1)
pdm09. Despite considerable genetic variation in cir-
culating A(H1N1)pdm09 viruses, very little antigenic
drift has been observed since the 2009 pandemic,
and the majority of the Argentinean isolates analysed
in this report were closely related to A/California/7/
2009, the recommended vaccine virus since 2009.
The low reactivity observed in A/Salta/1122/2012
was associated with a polymorphism at amino acid
position 156 of HA1, the normal aspartic acid being
present as a mixture of aspartic acid and asparagine.
Changes in the 153–157 region of HA1 have been
identified in many cell-propagated A(H1N1)pdm09
viruses, notably those isolated in SIAT cells, showing
low reactivity with post-infection ferret antisera raised
against A/California/7/2009, that are not present in
the corresponding clinical specimens [10].
The two A(H3N2) test viruses showed clear antigenic
divergence from the 2012 Southern Hemisphere vaccine
virus, A/Perth/16/2009, based onHI assay. They showed
significantly better reactivity with antisera raised against
five cell-propagated reference viruses, notably those four
with collection dates in 2011 and 2012 which included
the cell-propagated prototype of A/Victoria/361/2011.
An A/Victoria/361/2011-like virus was recommended
for the Southern Hemisphere 2013 influenza season.
As observed globally, in Argentina both lineages of
influenza type B co-circulated with the Victoria lin-
eage being prevalent. The B/Victoria lineage test
viruses were antigenically and genetically closely
related to cell-propagated surrogates of the 2012 vac-
cine virus, B/Brisbane/60/2008-like virus, as assessed
by HI assay.
A virus of the influenza B Yamagata lineage was not
included in the 2012 trivalent vaccine but this lineage,
although increasing in number in respect of both viruses
in genetic clades 2 and 3, remained the minority lineage
in 2012. Given the continued rise in the proportion of B
Yamagata lineage viruses, WHO recommended a clade
3 B/Wisconsin/1/2010-likeYamagata virus for use in the
2013 season [24]. The two clade 2 Yamagata lineage
viruses analysed here showed poor reactivity with anti-
serum raised against B/Wisconsin/1/2010 and a range of
other clade 3 viruses. Both viruses reactedwellwith anti-
serum raised against cell-propagated B/Estonia/55 669/
2011, a clade 2 virus (Table 4). The continued rise in
the proportion of Yamagata lineage viruses worldwide,
notably for clade 2, led to an amended recommendation
for the 2014 season of a clade 2 B/Massachusetts/2/
2012-like virus [28].
Globally, a limited number of sporadic oseltamivir-
resistant cases of A(H1N1)pdm09 have been reported
in the early phases of the pandemic, [29] and most re-
main sensitive to NAIs. Subtype-specific NA muta-
tions in framework or catalytic residues that confer
resistance to the antiviral drugs have been reported
in vitro and in vivo [30, 31]. NA-H275Y is the most fre-
quent change related to resistance to oseltamivir in A
(H1N1) and A(H5N1) [32, 33]. The first cases of
oseltamivir-resistance in A(H1N1)pdm09 viruses
were reported for specimens collected in Denmark
and Japan. The NA-N295S mutation was originally
reported in drug-resistant H5N1 viruses [34]. In the
course of the present study we detected an A(H1N1)
pdm09 virus, A/Salta/1341/2012 showing highly
reduced inhibition by oseltamivir and reduced inhib-
ition by zanamivir which carried an NA-N295S sub-
stitution. In terms of influenza antiviral susceptibility
surveillance detection of N1 NA-H275Y is screened
for routinely. A disadvantage of following this meth-
odology is the possibility of failing to detect other
less frequent changes that could affect the susceptibil-
ity to antiviral drugs. While there are a number of
instances of resistant viruses being isolated from per-
sons who had either been treated or been in close con-
tact with an individual who had been treated with
oseltamivir, this virus was detected in an untreated
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hospitalized patient. Determining the origins and gen-
esis of such drug-resistant viruses, notably in the ab-
sence of drug pressure, the understanding of the
emergence and persistence of oseltamivir resistance
in relation to the evolution of influenza viruses, drug
use and pandemic preparedness, is important. The
NIC, together with the MoH, gives guidelines for
the notification, vaccination, diagnosis, management
and specific treatment of the acute respiratory infec-
tions at the beginning of each year, since the pandemic
A(H1N1)pdm09. For the specific influenza treatment,
the MoH acquires and distributes NAIs and provides
guidelines for their administration. This situation
emphasizes the need for ongoing virological surveil-
lance to determine the susceptibility of local strains
and detect emerging resistance to these antivirals.
Surveillance of antiviral resistance is an essential
tool in the clinical management of severe or compli-
cated influenza cases and is an important firstline de-
fence during a probable pandemic [35].
The Argentina NIC together with other Southern
Hemisphere NICs has contributed to the WHO’s deci-
sion to review, twice a year, the composition of the
influenza vaccine.
This report highlights the importance of NICs per-
forming antigenic and genetic surveillance of influenza
viruses in order to update the national ministries of
health recommendations and contributes to the
WHO twice yearly update on the composition of
influenza vaccines. Additionally, data obtained by
NICs contributes to global influenza surveillance,
which serves as the primary global alert mechanism
for detecting the emergence of novel influenza viruses
that could cause public health alerts and result in pan-
demics. Overall, such studies allow countries to update
measures for prevention and control of influenza as
emerging situations dictate.
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